|
13 Nov 2020 |
CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Muscle-Invasive Bladder Cancer
|
|
12 Nov 2020 |
Vor Biopharma Announces Exclusive License of Clinical-Stage CD33 CAR-T from National Cancer Institute
|
|
12 Nov 2020 |
UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms
|
|
12 Nov 2020 |
Cardior Pharmaceuticals Announces Positive Phase Ib Results of its Lead Compound CDR132L in Heart Failure
|
|
11 Nov 2020 |
Bioheng Announced Oral Presentation of Its Preliminary Results of CRISPR-Engineered Allogeneic CAR-T for r/r B-ALL Treatment at 2020 ASH Meeting
|
|
11 Nov 2020 |
Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry Age-Related Macular Degeneration
|
|
10 Nov 2020 |
Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
|
|
10 Nov 2020 |
American Gene Technologies Announces First Trial Participant Enrolled in Phase 1 Study of AGT103-T Against HIV
|
|
10 Nov 2020 |
Locus Biosciences signs contract with CARB-X to advance $14 million precision medicine program to develop crPhage™ product targeting Klebsiella pneumoniae infections
|
|
10 Nov 2020 |
Medigene's MAGE-A4-specific TCR-Ts detect and fight cancer cells independent of CD8 co-receptor
|
|
09 Nov 2020 |
Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
|
|
09 Nov 2020 |
Repertoire Immune Medicines Presents First Clinical Data on PRIME IL-15 Cell Therapy in Advanced Metastatic Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
|
09 Nov 2020 |
OncoMyx Announces Presentation of Preclinical Efficacy Data of Novel Oncolytic Immunotherapy at SITC 2020
|
|
09 Nov 2020 |
Exicure Presents Positive Clinical Data with Cavrotolimod at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
|
|
09 Nov 2020 |
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
|
|
09 Nov 2020 |
BioInvent and Transgene present data on next generation oncolytic virus BT-001 at the SITC 35[th] Anniversary Annual Meeting
|
|
09 Nov 2020 |
4D Pharma presents new data from two MRx0518 clinical trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
|
06 Nov 2020 |
Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU
|
|
06 Nov 2020 |
Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis
|
|
05 Nov 2020 |
Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology
|
|
05 Nov 2020 |
American Society of Hematology (ASH) Abstract Shows Initial Anti-Leukemic Activity of UCART22 in BALLI-01 Phase 1 Study in R/R Adult B-ALL
|
|
05 Nov 2020 |
Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric Hyperoxaluria
|
|
05 Nov 2020 |
PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter
|
|
04 Nov 2020 |
BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease
|
|
04 Nov 2020 |
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
|
